Caredx (CDNA) closed at $77.88 on November 13, 2026, down 2.4% from the previous close, on volume of 682,162 shares (30-day average 1,349,408).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Put Spread | 19-Feb-2765 : 80 P | 1,048 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
CareDx is a new Overweight at Piper Sandler on transplant testing opportunity
Seeking Alpha News (Wed, 11-Nov 12:52 PM ET)
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and CareDx (CDNA)
TipRanks (Wed, 11-Nov 4:10 AM ET)
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 6-Nov 4:05 PM ET)
CareDx Announces Third KOAR Analysis Published in Transplantation
Business Wire (Tue, 3-Nov 7:05 AM ET)
CareDx soars as Q3 revenue hits $139M and 2026 guidance jumps to $520M–$530M
Market Chameleon (Fri, 30-Oct 6:02 AM ET)
CareDx Announces Third Quarter 2026 Financial Results
Business Wire (Thu, 29-Oct 4:01 PM ET)
Business Wire (Thu, 22-Oct 7:05 AM ET)
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Business Wire (Thu, 15-Oct 4:01 PM ET)
CareDx’s New Executive Advisor Receives 15,822 RSU Award—What This Could Mean for Stakeholders
Market Chameleon (Mon, 3-Aug 7:45 AM ET)
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Caredx trades on the NASDAQ stock market under the symbol CDNA.
As of November 13, 2026, CDNA stock price declined to $77.88 with 682,162 million shares trading.
CDNA has a beta of 0.49, meaning it tends to be less sensitive to market movements. CDNA has a correlation of 0.01 to the broad based SPY ETF.
CDNA has a market cap of $4.09 billion. This is considered a Mid Cap stock.
Last quarter Caredx reported $139 million in Revenue and $.70 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.48.
In the last 3 years, CDNA traded as high as $90.87 and as low as $7.42.
The top ETF exchange traded funds that CDNA belongs to (by Net Assets): XBI, IWM, VTI, ARKG, IWO.
CDNA has outperformed the market in the last year with a return of +390.7%, while the SPY ETF gained +13.4%. In the last 3 month period, CDNA beat the market returning +64.4%, while SPY returned -2.8%. However, in the most recent 2 weeks CDNA has underperformed the stock market by returning -10.9%, while SPY returned -0.2%.
CDNA support price is $76.37 and resistance is $83.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDNA shares will trade within this expected range on the day.
